Address: No. 20, Zhichun Rd., Haidian District, Beijing,China
Tel: -82080673
China Pharmaceutical Industry Association (CPIA) was founded in September 1988 and it is a non-governmental, non-profit association, Its members are mainly from large and medium sized pharmaceutical corporations, pharmaceutical machinery and medicinal glass packaging companies, regional pharmaceutical industrial associations, pharmaceutical research institutions, designing institutes, universities, colleges and secondary schools of this sector etc. CPIA is a national level society registered in the Ministry of Civil Affairs. The State-owned Assets Supervision and Administration Commission of the State Council directly administer the association. CPIA is a member and also a standing council director’s unit of China Federation of Industrial Economics.
Now CPIA has 338 members, the industrial output value of which (added together) is nearly up to 80 percent of that of the whole China’s pharmaceutical industry. CPIA also has 15 professional working units: 2 branch associations, 13 working & coordinating committees and communication groups.
Industry association
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group. Could you highlight the…
In 2013, Chinese President Xi Jinping launched the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative, corralling the two Special Administrative Regions (SARs) of Hong Kong and Macao with Guangdong, one…
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Chinese ecommerce behemoths Alibaba and JD.com are being used to buy and sell tens of thousands of prescription medicines, skirting regulations in what is a legal grey area. According to…
Andy A. Liu, CEO of CW Data Technologies, a joint venture between WuXi AppTec and China Electronics Data Corporation at the intersection of Big Data and healthcare, discusses emerging trends…
Simon Yam, managing director of Geodis Greater China, shares the importance of the Greater China region to Geodis globally, the region’s strong performance and growth, the strategic importance of the…
Gene Shigekawa, managing partner of MAZ World, shares their recent move to the Hong Kong Science and Technology Park (HKSTP) in 2017, the revolutionary ostrich-derived antibody they hope to further…
Louis Sze, CEO of Personal Surgical Modelling, an exciting Hong Kong start-up in the 3D printing medical technology field, shares the company’s achievements over the past few years, his insights…
K P Tsang, president of the Hong Kong Alliance for Rare Diseases (HKARD), shares the challenges faced by patients with rare diseases and their caregivers in Hong Kong, the areas…
Dr. Harley Seyedin, president of AmCham South China, talks up increasing connectivity in the region, competition and collaboration between the Greater Bay Area cities, and their potential for international life…
Rupert Mok, a veteran of the Hong Kong medtech industry, discusses regulatory alignment between Hong Kong and mainland China, opportunities for collaboration, the consumer ‘wearable’ space, and the state of…
This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities…
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates…
See our Cookie Privacy Policy Here
